BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-tainturier M, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93. [DOI: 10.1053/jhep.2002.33324] [Cited by in Crossref: 329] [Cited by in F6Publishing: 301] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 144] [Article Influence: 8.8] [Reference Citation Analysis]
2 Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract 2007;13:300-12. [PMID: 17599864 DOI: 10.4158/EP.13.3.300] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
3 Frydrychowicz A, Landgraf BR, Niespodzany E, Verma RW, Roldán-Alzate A, Johnson KM, Wieben O, Reeder SB. Four-dimensional velocity mapping of the hepatic and splanchnic vasculature with radial sampling at 3 tesla: a feasibility study in portal hypertension. J Magn Reson Imaging. 2011;34:577-584. [PMID: 21751287 DOI: 10.1002/jmri.22712] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
4 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
5 Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, Reynolds RM, Strachan MW. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM. 2012;105:425-432. [PMID: 22156706 DOI: 10.1093/qjmed/hcr233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
6 Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34:634-637. [PMID: 19195623 DOI: 10.1016/s1262-3636(08)74597-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 39] [Article Influence: 6.9] [Reference Citation Analysis]
7 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am. 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2004.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008;4:575-596. [PMID: 18827908 DOI: 10.2147/vhrm.s1991] [Cited by in Crossref: 131] [Cited by in F6Publishing: 89] [Article Influence: 10.1] [Reference Citation Analysis]
9 Aby ES, Lee E, Saggi SS, Viramontes MR, Grotts JF, Agopian VG, Busuttil RW, Saab S. Pretransplant Sarcopenia in Patients With NASH Cirrhosis Does Not Impact Rehospitalization or Mortality. Journal of Clinical Gastroenterology 2019;53:680-5. [DOI: 10.1097/mcg.0000000000001109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci. 2012;13:579-595. [PMID: 22312273 DOI: 10.3390/ijms13010579] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
11 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011; 17(36): 4055-4062 [PMID: 22039318 DOI: 10.3748/wjg.v17.i36.4055] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
14 Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13:1180-1186. [PMID: 16076987 DOI: 10.1038/oby.2005.140] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 8.7] [Reference Citation Analysis]
15 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 112] [Article Influence: 13.2] [Reference Citation Analysis]
16 Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459-464. [PMID: 18387499 DOI: 10.1016/j.cgh.2008.02.012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
17 Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79. [PMID: 25921668 DOI: 10.1016/j.cld.2015.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 15.7] [Reference Citation Analysis]
18 Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007;11:75-104, ix. [PMID: 17544973 DOI: 10.1016/j.cld.2007.02.011] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 7.4] [Reference Citation Analysis]
19 Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299-310. [PMID: 19857603 DOI: 10.1016/j.bbalip.2009.10.007] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 14.8] [Reference Citation Analysis]
20 Yan E, Durazo F, Tong M, Hong K. Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. Nutrition Reviews 2007;65:376-84. [DOI: 10.1111/j.1753-4887.2007.tb00315.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
21 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
22 Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, Yoon SK. Obesity and the risk of primary liver cancer: A systematic review and meta-analysis. Clin Mol Hepatol 2021;27:157-74. [PMID: 33238333 DOI: 10.3350/cmh.2020.0176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Lyall MJ, Cartier J, Thomson JP, Cameron K, Meseguer-Ripolles J, O'Duibhir E, Szkolnicka D, Villarin BL, Wang Y, Blanco GR, Dunn WB, Meehan RR, Hay DC, Drake AJ. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. Philos Trans R Soc Lond B Biol Sci 2018;373:20170362. [PMID: 29786565 DOI: 10.1098/rstb.2017.0362] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
24 Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, Hur C. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Netw Open 2019;2:e190047. [PMID: 30794300 DOI: 10.1001/jamanetworkopen.2019.0047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
25 Woodford RM, Burton PR, O'Brien PE, Laurie C, Brown WA. Laparoscopic Adjustable Gastric Banding In Patients with Unexpected Cirrhosis: Safety and Outcomes. Obes Surg. 2015;25:1858-1862. [PMID: 25708241 DOI: 10.1007/s11695-015-1623-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
26 Kennedy C, Redden D, Gray S, Eckhoff D, Massoud O, McGuire B, Alkurdi B, Bloomer J, DuBay DA. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford). 2012;14:625-634. [PMID: 22882200 DOI: 10.1111/j.1477-2574.2012.00497.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
27 Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Intern Med 2017;56:1459-65. [PMID: 28626169 DOI: 10.2169/internalmedicine.56.7830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21. [PMID: 31475372 DOI: 10.1111/apt.15464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
29 李爽. 非酒精性脂肪性肝病显著肝纤维化的无创诊断. 世界华人消化杂志 2012; 20(3): 233-237 [DOI: 10.11569/wcjd.v20.i3.233] [Reference Citation Analysis]
30 Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2003;4:611-623. [PMID: 12739988 DOI: 10.1517/14656566.4.5.611] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
31 Dyer Z, Peltekian K, Veldhuyzen Van Zanten S. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 2005;22:17-22. [DOI: 10.1111/j.1365-2036.2005.02504.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
32 Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-35. [PMID: 20870345 DOI: 10.1016/j.ultrasmedbio.2010.07.005] [Cited by in Crossref: 434] [Cited by in F6Publishing: 388] [Article Influence: 39.5] [Reference Citation Analysis]
33 Park KG, Min AK, Koh EH, Kim HS, Kim MO, Park HS, Kim YD, Yoon TS, Jang BK, Hwang JS. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology. 2008;48:1477-1486. [PMID: 18972440 DOI: 10.1002/hep.22496] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 9.5] [Reference Citation Analysis]
34 Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol 2015;1:646-663.e4. [PMID: 26783552 DOI: 10.1016/j.jcmgh.2015.07.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 13.7] [Reference Citation Analysis]
35 Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T;  LIDO Study Group;  CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [PMID: 16503961 DOI: 10.1186/1471-230x-6-6] [Cited by in Crossref: 290] [Cited by in F6Publishing: 109] [Article Influence: 19.3] [Reference Citation Analysis]
36 Willy Haukeland J, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2009;40:1469-77. [DOI: 10.1080/00365520500264953] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
37 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
38 Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related. Am J Gastroenterol 2004;99:76-81. [DOI: 10.1046/j.1572-0241.2003.04013.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
39 Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med 2017;5:161. [PMID: 28480197 DOI: 10.21037/atm.2017.03.107] [Cited by in Crossref: 246] [Cited by in F6Publishing: 212] [Article Influence: 61.5] [Reference Citation Analysis]
40 Jawairia M, Subhani M, Siddiqui G, Prasad A, Shahzad G, Rizvon K, Mustacchia P. Unexplained findings of kayser-fleischer-like rings in a patient with cryptogenic cirrhosis. Case Rep Gastrointest Med 2012;2012:438525. [PMID: 22606437 DOI: 10.1155/2012/438525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
41 Calle-toro JS, Barrera CA, Khrichenko D, Otero HJ, Serai SD. R2 relaxometry based MR imaging for estimation of liver iron content: A comparison between two methods. Abdom Radiol 2019;44:3058-68. [DOI: 10.1007/s00261-019-02074-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
42 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
43 Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-967. [PMID: 20376504 DOI: 10.1007/s00535-010-0237-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
44 Younossi ZM, Gramlich T, Matteoni CA, Boparai N, Mccullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology 2004;2:262-5. [DOI: 10.1016/s1542-3565(04)00014-x] [Cited by in Crossref: 259] [Cited by in F6Publishing: 90] [Article Influence: 15.2] [Reference Citation Analysis]
45 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
46 Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375-378. [PMID: 16012969 DOI: 10.1053/j.gastro.2005.05.041] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 6.4] [Reference Citation Analysis]
47 Hayashi T, Fukuzawa K, Kondo H, Onodera H, Toyotaka S, Tojo R, Yano S, Tano M, Miyati T, Kotoku J, Okamoto T, Toyoda K, Oba H. Influence of Gd-EOB-DTPA on proton density fat fraction using the six-echo Dixon method in 3 Tesla magnetic resonance imaging. Radiol Phys Technol 2017;10:483-8. [DOI: 10.1007/s12194-017-0420-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Cadranel JF, Jouannaud V, Loison S. [Improving insulin resistance: certain progress in the management of patients with non-alcoholic steatohepatitis...but the story continues]. Gastroenterol Clin Biol 2004;28:265-7. [PMID: 15094675 DOI: 10.1016/s0399-8320(04)94916-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27:195-208. [PMID: 23731881 DOI: 10.1016/j.beem.2013.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
50 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 166] [Article Influence: 14.7] [Reference Citation Analysis]
51 Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol. 2009;193:14-27. [PMID: 19542391 DOI: 10.2214/ajr.09.2601] [Cited by in Crossref: 128] [Cited by in F6Publishing: 46] [Article Influence: 10.7] [Reference Citation Analysis]
52 Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450-465. [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 165] [Article Influence: 12.0] [Reference Citation Analysis]
53 Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer Lett 2014;345:230-4. [PMID: 23941829 DOI: 10.1016/j.canlet.2013.07.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
54 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 601] [Article Influence: 57.9] [Reference Citation Analysis]
55 Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015;14:119-127. [PMID: 26114083 DOI: 10.1007/s11901-015-0260-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
56 McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3-23. [PMID: 15757802 DOI: 10.1016/j.bpg.2004.10.004] [Cited by in Crossref: 214] [Cited by in F6Publishing: 195] [Article Influence: 13.4] [Reference Citation Analysis]
57 Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2007;19:827-834. [PMID: 17873605 DOI: 10.1097/meg.0b013e3282748ef2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
58 Mohamed AA, Elsaid OM, Amer EA, Elosaily HH, Sleem MI, Gerges SS, Saleh MA, El Shimy A, El Abd YS. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017;8:343-9. [PMID: 28417047 DOI: 10.1016/j.jare.2017.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:325-34. [PMID: 21922031 DOI: 10.1177/1756283X11409793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
61 Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004;444:3-12. [PMID: 14685853 DOI: 10.1007/s00428-003-0943-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
62 Parafati M, Bae SH, Kirby RJ, Fitzek M, Iyer P, Engkvist O, Smith DM, Malany S. Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation. Int J Mol Sci 2020;21:E9557. [PMID: 33334026 DOI: 10.3390/ijms21249557] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Lee JY, Kim KM, Lee SG, Yu E, Lim Y, Lee HC, Chung Y, Lee YS, Suh D. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 2007;47:239-44. [DOI: 10.1016/j.jhep.2007.02.007] [Cited by in Crossref: 176] [Cited by in F6Publishing: 158] [Article Influence: 12.6] [Reference Citation Analysis]
64 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatol Int 2013;7:850-8. [DOI: 10.1007/s12072-012-9419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
66 Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M, Auton A, Wang T, Wolkoff AW, Morrow BE. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med 2015;3:558-69. [PMID: 26740948 DOI: 10.1002/mgg3.168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
67 Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. 2003;39:1049-1055. [PMID: 14642625 DOI: 10.1016/s0168-8278(03)00456-2] [Cited by in Crossref: 116] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
68 Le D, Marks D, Lyle E, Corless CL, Diggs BS, Jobe BA, Kay T, Deveney CW, Wolfe BM, Roberts CT. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21:1593-1599. [PMID: 17294310 DOI: 10.1007/s00464-006-9185-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
69 Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595-617, x. [PMID: 15331066 DOI: 10.1016/j.cld.2004.04.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 4.7] [Reference Citation Analysis]
70 Barroso MV, Graça-Reis A, Cattani-Cavalieri I, Gitirana LB, Valenca SS, Lanzetti M. Mate tea reduces high fat diet-induced liver and metabolic disorders in mice. Biomed Pharmacother 2019;109:1547-55. [PMID: 30551407 DOI: 10.1016/j.biopha.2018.11.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
71 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 95] [Article Influence: 12.5] [Reference Citation Analysis]
72 Kawamura Y, Arase Y, Ikeda K, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Inao M, Mochida S, Kumada H. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:597-605. [PMID: 26707683 DOI: 10.1016/j.cgh.2015.11.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
73 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
74 Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 221] [Article Influence: 20.6] [Reference Citation Analysis]
75 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1373] [Article Influence: 88.1] [Reference Citation Analysis]
76 Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care. 2015;4:45-52. [PMID: 25810989 DOI: 10.4103/2249-4863.152252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
77 Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13(39): 5180-5187 [PMID: 17876888 DOI: 10.3748/wjg.v13.i39.5180] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
78 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 23.4] [Reference Citation Analysis]
79 Stephenson K, Kennedy L, Hargrove L, Demieville J, Thomson J, Alpini G, Francis H. Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights. Gene Expr. 2018;18:5-17. [PMID: 29096730 DOI: 10.3727/105221617x15093707969658] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
80 Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48-55. [PMID: 15654780 DOI: 10.1111/j.1572-0241.2005.40429.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 5.8] [Reference Citation Analysis]
81 Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851-859. [PMID: 19115377 DOI: 10.1002/hep.22734] [Cited by in Crossref: 377] [Cited by in F6Publishing: 338] [Article Influence: 31.4] [Reference Citation Analysis]
82 Rath MM, Panigrahi MK, Pattnaik K, Bhuyan P, Kar SK, Misra B, Misra D, Meher C, Agrawal O, Rath J, Singh SP. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. J Clin Exp Hepatol 2016;6:291-6. [PMID: 28003718 DOI: 10.1016/j.jceh.2016.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
83 Ratziu V, Vispo M, Tahiri M, Bonyhay L, de Torres M, Bernhardt C, Poynard T, Lebray P. Peut-on traiter la stéatohépatite métabolique ? Gastroentérologie Clinique et Biologique 2007;31:333-40. [DOI: 10.1016/s0399-8320(07)89386-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Calle-Toro JS, Serai SD, Hartung EA, Goldberg DJ, Bolster BD Jr, Darge K, Anupindi SA. Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease. Abdom Radiol (NY) 2019;44:894-902. [PMID: 30600386 DOI: 10.1007/s00261-018-1884-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
85 Zanfirescu A, Ungurianu A, Tsatsakis AM, Nițulescu GM, Kouretas D, Veskoukis A, Tsoukalas D, Engin AB, Aschner M, Margină D. A review of the alleged health hazards of monosodium glutamate. Compr Rev Food Sci Food Saf 2019;18:1111-34. [PMID: 31920467 DOI: 10.1111/1541-4337.12448] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
86 Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002;97:2714-2724. [PMID: 12425538 DOI: 10.1111/j.1572-0241.2002.07069.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 46] [Article Influence: 0.5] [Reference Citation Analysis]
87 Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J MagnReson Imaging. 2010;31:589-600. [PMID: 20187201 DOI: 10.1002/jmri.22081] [Cited by in Crossref: 286] [Cited by in F6Publishing: 269] [Article Influence: 26.0] [Reference Citation Analysis]
88 Moreno-Sánchez D. [Epidemiology and natural history of primary nonalcoholic fatty liver disease]. Gastroenterol Hepatol 2006;29:244-54. [PMID: 16584696 DOI: 10.1157/13085972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
89 Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, Chu WC, Chan HL. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182-189. [PMID: 25195550 DOI: 10.1016/j.jhep.2014.08.041] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 13.4] [Reference Citation Analysis]
90 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 14.1] [Reference Citation Analysis]
91 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
92 Hájek M, Dezortová M, Wagnerová D, Škoch A, Voska L, Hejlová I, Trunečka P. MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients. Magn Reson Mater Phy 2011;24:297-304. [DOI: 10.1007/s10334-011-0264-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
93 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
94 Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016;65:1151-60. [DOI: 10.1016/j.metabol.2016.01.010] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 16.8] [Reference Citation Analysis]
95 Takahashi T, Nishida T, Baba H, Hatta H, Imura J, Sutoh M, Toyohara S, Hokao R, Watanabe S, Ogawa H, Uehara H, Tsuneyama K. Histopathological characteristics of glutamine synthetase-positive hepatic tumor lesions in a mouse model of spontaneous metabolic syndrome (TSOD mouse). Mol Clin Oncol 2016;5:267-70. [PMID: 27446562 DOI: 10.3892/mco.2016.924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
96 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 294] [Article Influence: 28.9] [Reference Citation Analysis]
97 Obulhasim G, Yasen M, Kajino K, Mogushi K, Tanaka S, Mizushima H, Tanaka H, Arii S, Hino O. Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome. Hepatol Int 2013;7:215-25. [PMID: 26201636 DOI: 10.1007/s12072-012-9357-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Takizawa D, Kakizaki S, Horiguchi N, Yamazaki Y, Tojima H, Mori M. Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. Carcinogenesis 2011;32:576-83. [PMID: 21173431 DOI: 10.1093/carcin/bgq277] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
99 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 7.3] [Reference Citation Analysis]
100 El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA, Slankamenac K, Graf R, Clavien PA. Assessment of hepatic steatosis by expert pathologists: The end of a gold standard. Ann Surg. 2009;250:691-697. [PMID: 19806055 DOI: 10.1097/sla.0b013e3181bcd6dd] [Cited by in Crossref: 193] [Cited by in F6Publishing: 72] [Article Influence: 16.1] [Reference Citation Analysis]
101 Méndez-sánchez; N, Vásquez-fernández; F, Zamora-valdés; D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology 2008;7:46-51. [DOI: 10.1016/s1665-2681(19)31886-1] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
102 Chen C, Liu Q, Liu L, Hu YY, Feng Q. Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease. Mol Nutr Food Res 2018;62. [PMID: 28799714 DOI: 10.1002/mnfr.201700483] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
103 Miyaoka H, Michitaka K, Tokumoto Y, Miyake T, Shigematsu S, Soga Y, Abe M, Hiasa Y, Matsuura B, Horiike N, Onji M. LAPAROSCOPIC FEATURES AND INTEROBSERVER VARIATION OF HISTOLOGICAL DIAGNOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: LAPAROSCOPY AND HISTOLOGY OF NAFLD. Digestive Endoscopy 2008;20:22-8. [DOI: 10.1111/j.1443-1661.2007.00771.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125-1149, ix. [PMID: 17964913 DOI: 10.1016/j.mcna.2007.06.001] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.1] [Reference Citation Analysis]
105 Kennedy L, Meadows V, Sybenga A, Demieville J, Chen L, Hargrove L, Ekser B, Dar W, Ceci L, Kundu D, Kyritsi K, Pham L, Zhou T, Glaser S, Meng F, Alpini G, Francis H. Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet. Hepatology 2021;74:164-82. [PMID: 33434322 DOI: 10.1002/hep.31713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006;25:3756-3770. [PMID: 16799617 DOI: 10.1038/sj.onc.1209557] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 5.6] [Reference Citation Analysis]
107 Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res. 2013;37 Suppl 1:E247-E252. [PMID: 23320802 DOI: 10.1111/j.1530-0277.2012.01900.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
108 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
110 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;19:368-374. [PMID: 15012772 DOI: 10.1111/j.1440-1746.2003.03252.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
112 Wu SJ. Osthole Attenuates Inflammatory Responses and Regulates the Expression of Inflammatory Mediators in HepG2 Cells Grown in Differentiated Medium from 3T3-L1 Preadipocytes. J Med Food 2015;18:972-9. [PMID: 25876063 DOI: 10.1089/jmf.2014.3314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
113 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
114 Maheshwari A, Thuluvath PJ. Cryptogenic Cirrhosis and NAFLD: Are They Related? Am J Gastroenterology 2006;101:664-8. [DOI: 10.1111/j.1572-0241.2006.00478.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
115 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
116 Syn WK, Yang L, Chiang DJ, Qian Y, Jung Y, Karaca G, Choi SS, Witek RP, Omenetti A, Pereira TA, Diehl AM. Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int 2009;29:1262-72. [PMID: 19490416 DOI: 10.1111/j.1478-3231.2009.02036.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
117 Yatsuji S, Hashimoto E, Tobari M, Tokushige K, Shiratori K. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res. 2007;37:1034-1043. [PMID: 17610504 DOI: 10.1111/j.1872-034x.2007.00156.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
118 Merriman RB. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006;3:113-7. [PMID: 16970837 DOI: 10.1007/BF02696654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
119 Hayashi T, Saitoh S, Fukuzawa K, Tsuji Y, Takahashi J, Kawamura Y, Akuta N, Kobayashi M, Ikeda K, Fujii T, Miyati T, Kumada H. Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2017;11:674-83. [PMID: 28651300 DOI: 10.5009/gnl16440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
120 Lemoine M. Stéatopathie métabolique: définition et histoire naturelle. Gastroentérologie Clinique et Biologique 2009;33:398-404. [DOI: 10.1016/j.gcb.2009.02.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
121 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580-585. [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
122 Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol. 2012;43:737-746. [PMID: 22018903 DOI: 10.1016/j.humpath.2011.07.005] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 10.0] [Reference Citation Analysis]
123 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 387] [Article Influence: 45.9] [Reference Citation Analysis]
124 Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H, Shiratori K, Takasaki K. Comparison of Hepatocellular Carcinoma Patients With Alcoholic Liver Disease and Nonalcoholic Steatohepatitis. Alcoholism Clin Exp Res 2004;28:164S-8S. [DOI: 10.1111/j.1530-0277.2004.tb03237.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
125 Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395-1400. [PMID: 16105127 DOI: 10.1111/j.1440-1746.2005.04007.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
126 Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009. [PMID: 19691668 DOI: 10.1111/j.1365-2036.2009.04122.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
127 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1239-1244. [PMID: 20505515 DOI: 10.1097/meg.0b013e32833aa19b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
128 Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29:1431-1438. [PMID: 19422483 DOI: 10.1111/j.1478-3231.2009.02022.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 7.8] [Reference Citation Analysis]
129 Ricardo de Andrade A, Cotrim HP, Alves E, Soares D, Rocha R, Almeida A, Almeida CG, Antonio de Freitas L. Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. Annals of Hepatology 2008;7:364-8. [DOI: 10.1016/s1665-2681(19)31838-1] [Cited by in Crossref: 22] [Article Influence: 1.7] [Reference Citation Analysis]
130 Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004] [Cited by in Crossref: 434] [Cited by in F6Publishing: 426] [Article Influence: 28.9] [Reference Citation Analysis]
131 Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc 2003;35:2977-80. [PMID: 14697954 DOI: 10.1016/j.transproceed.2003.10.059] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
132 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2007;4:432-41. [DOI: 10.1038/ncpgasthep0879] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
133 Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00505-X. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996-1005. [PMID: 19546889 DOI: 10.1038/cr.2009.73] [Cited by in Crossref: 130] [Cited by in F6Publishing: 134] [Article Influence: 10.8] [Reference Citation Analysis]
135 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 10.5] [Reference Citation Analysis]
136 Phisalprapa P, Prasitwarachot R, Kositamongkol C, Hengswat P, Srivanichakorn W, Washirasaksiri C, Treeprasertsuk S, Charatcharoenwitthaya P, Chaiyakunapruk N. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol 2021;21:135. [PMID: 33765931 DOI: 10.1186/s12876-021-01720-w] [Reference Citation Analysis]
137 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 403] [Article Influence: 32.4] [Reference Citation Analysis]
138 Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129-137. [PMID: 20299294 DOI: 10.1016/j.pcd.2010.02.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
139 Wang W, Zhong X, Guo J. Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review). Int J Mol Med 2021;47:114. [PMID: 33907839 DOI: 10.3892/ijmm.2021.4947] [Reference Citation Analysis]
140 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
141 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. [PMID: 16447287 DOI: 10.1002/hep.20973] [Cited by in Crossref: 1618] [Cited by in F6Publishing: 1553] [Article Influence: 107.9] [Reference Citation Analysis]
142 Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10:S69-S73. [PMID: 14762843 DOI: 10.1002/lt.20033] [Cited by in Crossref: 151] [Cited by in F6Publishing: 131] [Article Influence: 8.9] [Reference Citation Analysis]
143 Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
144 Shukla A, Kapileswar S, Gogtay N, Joshi A, Dhore P, Shah C, Abraham P, Bhatia S. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2015;34:281-5. [DOI: 10.1007/s12664-015-0580-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
145 Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003;5:253-9. [DOI: 10.1007/s11894-003-0028-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
146 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5-13. [PMID: 15962320 DOI: 10.1002/hep.20750] [Cited by in Crossref: 250] [Cited by in F6Publishing: 242] [Article Influence: 15.6] [Reference Citation Analysis]
147 Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2010;22:18-23. [DOI: 10.1097/meg.0b013e32832e2baf] [Cited by in Crossref: 75] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
148 Terakura D, Shimizu M, Iwasa J, Baba A, Kochi T, Ohno T, Kubota M, Shirakami Y, Shiraki M, Takai K, Tsurumi H, Tanaka T, Moriwaki H. Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis 2012;33:2499-506. [PMID: 23027617 DOI: 10.1093/carcin/bgs303] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
149 Kadayifci A, Merriman RB, Bass NM. Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 2007;11:119-40. [DOI: 10.1016/j.cld.2007.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
150 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152. [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 12.7] [Reference Citation Analysis]
151 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
152 Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941-1952. [PMID: 23703580 DOI: 10.1002/hep.26461] [Cited by in Crossref: 258] [Cited by in F6Publishing: 239] [Article Influence: 32.3] [Reference Citation Analysis]
153 Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It’s time to get serious. Hepatology. 2006;44:802-805. [PMID: 17006914 DOI: 10.1002/hep.21391] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
154 El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol 2008; 14(26): 4120-4126 [PMID: 18636654 DOI: 10.3748/wjg.14.4120] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
155 Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2005;41:204-6. [PMID: 15619243 DOI: 10.1002/hep.20558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
156 Chávez-tapia NC, Méndez-sánchez N, Uribe M. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Annals of Hepatology 2009;8:S34-9. [DOI: 10.1016/s1665-2681(19)31824-1] [Cited by in Crossref: 12] [Article Influence: 1.0] [Reference Citation Analysis]
157 Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, Tamagawa Y, Fukui H. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol 2006; 12(13): 2080-2085 [PMID: 16610061 DOI: 10.3748/wjg.v12.i13.2080] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
158 Marmur J, Bergquist A, Stål P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand J Gastroenterol 2010;45:60-9. [PMID: 20030578 DOI: 10.3109/00365520903384742] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
159 Heo MJ, Yun J, Kim SG. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. Arch Pharm Res 2019;42:48-62. [PMID: 30610616 DOI: 10.1007/s12272-018-01104-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
160 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
161 Rosmorduc O. Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments? Ann Endocrinol (Paris). 2013;74:115-120. [PMID: 23597944 DOI: 10.1016/j.ando.2013.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
162 Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 199] [Article Influence: 14.9] [Reference Citation Analysis]
163 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
164 Ioannou GN, Weiss NS, Boyko EJ, Kowdley KV, Kahn SE, Carithers RL, Tsai EC, Dominitz JA. Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology 2005;3:67-74. [DOI: 10.1016/s1542-3565(04)00442-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
165 Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005;7:32-36. [PMID: 15701296 DOI: 10.1007/s11894-005-0063-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
166 Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, Ahn SH, Chon CY, Lee HW, Park Y. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102-109. [PMID: 24028214 DOI: 10.1111/liv.12282] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 12.4] [Reference Citation Analysis]
167 Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. [PMID: 17096854 DOI: 10.1186/1471-230x-6-34] [Cited by in Crossref: 186] [Cited by in F6Publishing: 71] [Article Influence: 12.4] [Reference Citation Analysis]
168 Hübscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2004;16:1107-1115. [PMID: 15489567 DOI: 10.1097/00042737-200411000-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
169 Arteel GE. Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH? Hepatology. 2012;55:2030-2032. [PMID: 22422583 DOI: 10.1002/hep.25721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
170 Vilar-gomez E, Calzadilla-bertot L, Wai-sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-fabian L, Alvarez-quiñones Sanz M, Conde-martin AF, De Boer B, Mcleod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-gomez M. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 2018;155:443-457.e17. [DOI: 10.1053/j.gastro.2018.04.034] [Cited by in Crossref: 235] [Cited by in F6Publishing: 226] [Article Influence: 78.3] [Reference Citation Analysis]
171 Kawamura Y, Ikeda K, Arase Y, Sorin Y, Fukushima T, Kunimoto H, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int. 2015;9:269-277. [PMID: 25788193 DOI: 10.1007/s12072-014-9605-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
172 Lonardo A, Bagni A, Tarugi P, Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol. 2004;16:1043-1050. [PMID: 15371930 DOI: 10.1097/00042737-200410000-00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
173 Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res 2014;44:854-62. [PMID: 23834322 DOI: 10.1111/hepr.12197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
174 Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol. 2003;98:2348-2350. [PMID: 14638333 DOI: 10.1111/j.1572-0241.2003.08695.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
175 Nakamura S, Konishi H, Kishino M, Yatsuji S, Tokushige K, Hashimoto E, Shiratori K. Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. Hepatol Res 2008;38:572-9. [PMID: 18328071 DOI: 10.1111/j.1872-034X.2008.00318.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
176 Duly AM, Alani B, Huang EY, Yee C, Haber PS, McLennan SV, Seth D. Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity. Nutr Diabetes. 2015;5:e154. [PMID: 25915743 DOI: 10.1038/nutd.2015.4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
177 De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-dall'antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007;87:792-806. [DOI: 10.1038/labinvest.3700590] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
178 Lahmek P, Nahon S. Stéatopathies hépatiques non alcooliques. EMC - Hépato-Gastroenterologie 2005;2:269-83. [DOI: 10.1016/j.emchg.2005.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Marchesini G, Forlani G, Bugianesi E. Is liver disease a threat to patients with metabolic disorders? Ann Med. 2005;37:333-346. [PMID: 16179269 DOI: 10.1080/07853890510011445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
180 Ruelas-villavicencio AL, Vargas-vorácková F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? Annals of Hepatology 2004;3:152-9. [DOI: 10.1016/s1665-2681(19)32093-9] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
181 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
182 Lemoine M, Serfaty L. [Nonalcoholic fatty liver disease]. Presse Med 2012;41:169-89. [PMID: 21723084 DOI: 10.1016/j.lpm.2011.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
183 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191-2207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 217] [Cited by in F6Publishing: 205] [Article Influence: 15.5] [Reference Citation Analysis]
185 Jung KS, Kim BK, Kim SU, Chon YE, Chun KH, Kim SB, Lee SH, Ahn SS, Park JY, Kim DY. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One. 2014;9:e98689. [PMID: 24901649 DOI: 10.1371/journal.pone.0098689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
186 Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, Monden M. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology. 2007;243:422-430. [PMID: 17356175 DOI: 10.1148/radiol.2432051244] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
187 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 116] [Article Influence: 16.9] [Reference Citation Analysis]
188 Caldwell S. Cryptogenic Cirrhosis: What Are We Missing? Curr Gastroenterol Rep 2010;12:40-8. [DOI: 10.1007/s11894-009-0082-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
189 Ratziu V, Tahiri M, Bonyhay L. La stéatohépatite non alcoolique. Annales d'Endocrinologie 2005;66:71-80. [DOI: 10.1016/s0003-4266(05)81735-4] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
190 Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009;44 Suppl 19:89-95. [PMID: 19148800 DOI: 10.1007/s00535-008-2262-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
192 Polasek M, Fuchs BC, Uppal R, Schühle DT, Alford JK, Loving GS, Yamada S, Wei L, Lauwers GY, Guimaraes AR, Tanabe KK, Caravan P. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012;57:549-55. [PMID: 22634342 DOI: 10.1016/j.jhep.2012.04.035] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 8.2] [Reference Citation Analysis]
193 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4(3): 51-63 [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 73] [Article Influence: 11.6] [Reference Citation Analysis]
194 Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207-218. [PMID: 17229244 DOI: 10.1111/j.1365-2036.2006.03182.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
195 Méndez-sánchez N, Villa AR, Vázquez-elizondo G, Ponciano-rodrí G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Annals of Hepatology 2008;7:226-9. [DOI: 10.1016/s1665-2681(19)31852-6] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
196 Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12(14): 2161-2167 [PMID: 16610015 DOI: 10.3748/wjg.v12.i14.2161] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
197 Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017;65:1156-1164. [PMID: 27880977 DOI: 10.1002/hep.28958] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
198 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
199 Lin M, Kao S, Chung P, Chan K, Yang M, Wang C. Improvement for High Fat Diet-Induced Hepatic Injuries and Oxidative Stress by Flavonoid-Enriched Extract from Nelumbo nucifera Leaf. J Agric Food Chem 2009;57:5925-32. [DOI: 10.1021/jf901058a] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
200 Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013;33:1062-70. [PMID: 23560860 DOI: 10.1111/liv.12165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
201 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012;36:202-8. [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
202 Lyall MJ, Thomson JP, Cartier J, Ottaviano R, Kendall TJ, Meehan RR, Drake AJ. Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics 2020;15:61-71. [PMID: 31389294 DOI: 10.1080/15592294.2019.1649527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
203 Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335. [PMID: 16355018 DOI: 10.1097/00000441-200512000-00011] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 8.5] [Reference Citation Analysis]
204 Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 2009;24:1669-1676. [PMID: 19788607 DOI: 10.1111/j.1440-1746.2009.06039.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
205 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191-207, x-xi. [PMID: 17544979 DOI: 10.1016/j.cld.2007.02.006] [Cited by in Crossref: 166] [Cited by in F6Publishing: 153] [Article Influence: 11.9] [Reference Citation Analysis]
207 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578-584. [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013] [Cited by in Crossref: 187] [Cited by in F6Publishing: 161] [Article Influence: 11.0] [Reference Citation Analysis]
208 Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44:1190-1194. [PMID: 19672551 DOI: 10.1007/s00535-009-0112-0] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 13.1] [Reference Citation Analysis]
209 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533, viii. [PMID: 15331061 DOI: 10.1016/j.cld.2004.04.004] [Cited by in Crossref: 349] [Cited by in F6Publishing: 321] [Article Influence: 20.5] [Reference Citation Analysis]
210 Hayashi T, Fukuzawa K, Yamazaki H, Konno T, Miyati T, Kotoku J, Oba H, Kondo H, Toyoda K, Saitoh S. Multicenter, multivendor phantom study to validate proton density fat fraction and T2* values calculated using vendor-provided 6-point DIXON methods. Clinical Imaging 2018;51:38-42. [DOI: 10.1016/j.clinimag.2018.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
211 Ratziu V, Pienar L. Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? Hepatol Res 2011;41:687-95. [PMID: 21711428 DOI: 10.1111/j.1872-034X.2011.00825.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
212 Clouston A. An approach to the surgical pathology of tumours and tumour-like conditions of the liver. Pathology 2004;36:5-18. [DOI: 10.1080/00313020310001648413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Liu D, Li S, Li Z. Adiponectin: A biomarker for chronic hepatitis C? Cytokine 2017;89:27-33. [PMID: 26683021 DOI: 10.1016/j.cyto.2015.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
214 Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history? Am J Gastroenterol. 2003;98:1915-1917. [PMID: 14499766 DOI: 10.1111/j.1572-0241.2003.07667.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
215 Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; The Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010;45:86-94. [DOI: 10.1007/s00535-009-0128-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 7.6] [Reference Citation Analysis]
216 Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T;  LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110. [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078] [Cited by in Crossref: 421] [Cited by in F6Publishing: 381] [Article Influence: 32.4] [Reference Citation Analysis]
217 Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 272] [Article Influence: 20.9] [Reference Citation Analysis]
218 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.9] [Reference Citation Analysis]
219 Viganò L, Conci S, Cescon M, Fava C, Capelli P, D'Errico A, Torzilli G, Di Tommaso L, Giuliante F, Vecchio FM, Salizzoni M, David E, Pinna AD, Guglielmi A, Capussotti L. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC. J Hepatol 2015;63:93-101. [PMID: 25646890 DOI: 10.1016/j.jhep.2015.01.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
220 Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18-25. [DOI: 10.1007/s11894-003-0005-y] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
221 Xin X, Chen C, Hu YY, Feng Q. Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD). Biomed Pharmacother 2019;117:109047. [PMID: 31176163 DOI: 10.1016/j.biopha.2019.109047] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
222 Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien P. Serotonin Mediates Oxidative Stress and Mitochondrial Toxicity in a Murine Model of Nonalcoholic Steatohepatitis. Gastroenterology 2007;133:608-18. [DOI: 10.1053/j.gastro.2007.05.019] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 7.2] [Reference Citation Analysis]
223 Poulsen MM, Larsen JØ, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK, Kjær TN, Richelsen B, Pedersen SB. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 2012;32:701-8. [PMID: 23084643 DOI: 10.1016/j.nutres.2012.08.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
224 Page L, Girling J. A novel cause for abnormal liver function tests in pregnancy and the puerperium: non-alcoholic fatty liver disease: A novel cause for abnormal liver function tests in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 2011;118:1532-5. [DOI: 10.1111/j.1471-0528.2011.03070.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
225 Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004;35:1070-82. [PMID: 15343508 DOI: 10.1016/j.humpath.2004.04.017] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 6.6] [Reference Citation Analysis]
226 Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2020;36:235-43. [PMID: 31631714 DOI: 10.1080/03007995.2019.1683817] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
227 Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5:27-42. [PMID: 14969505 DOI: 10.1111/j.1467-789x.2004.00126.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 65] [Article Influence: 10.9] [Reference Citation Analysis]
228 Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13-20. [PMID: 21920839 DOI: 10.1016/j.clinre.2011.08.001] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 13.5] [Reference Citation Analysis]
229 Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, Leandro G, Arvaniti V, Germani G, Patch D. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 2011;31:730-739. [PMID: 21457446 DOI: 10.1111/j.1478-3231.2011.02488.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
230 Lee HW, Kim KJ, Jung KS, Chon YE, Huh JH, Park KH, Chung JB, Kim CO, Han KH, Park JY. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS One. 2017;12:e0187066. [PMID: 29077769 DOI: 10.1371/journal.pone.0187066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
231 Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet. Biochemical and Biophysical Research Communications 2007;364:801-7. [DOI: 10.1016/j.bbrc.2007.10.083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
232 Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clinics in Liver Disease 2004;8:619-38. [DOI: 10.1016/j.cld.2004.04.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
233 Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int. 2008;28:650-658. [PMID: 18331241 DOI: 10.1111/j.1478-3231.2008.01693.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
234 Miyazaki T, Shirakami Y, Kubota M, Ideta T, Kochi T, Sakai H, Tanaka T, Moriwaki H, Shimizu M. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget 2016;7:10448-58. [PMID: 26871288 DOI: 10.18632/oncotarget.7249] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
235 Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248-254. [PMID: 19032450 DOI: 10.1111/j.1440-1746.2008.05640.x] [Cited by in Crossref: 214] [Cited by in F6Publishing: 196] [Article Influence: 16.5] [Reference Citation Analysis]
236 Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005;22 Suppl 2:40-43. [PMID: 16225471 DOI: 10.1111/j.1365-2036.2005.02594.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
237 Cortez-pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Practice & Research Clinical Gastroenterology 2004;18:1089-104. [DOI: 10.1016/j.bpg.2004.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
238 Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 2012;42:767-773. [PMID: 22487102 DOI: 10.1111/j.1872-034x.2012.00986.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
239 Siegel AB, Wang S, Jacobson JS, Hershman DL, Lim EA, Yu J, Ferrante L, Devaraj KM, Remotti H, Scrudato S, Halazun K, Emond J, Dove L, Brown RS Jr, Neugut AI. Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest 2010;28:1063-9. [PMID: 21077757 DOI: 10.3109/07357907.2010.483500] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
240 Watanabe S, Shibukawa S, Hayashi T, Tsuruya K, Niwa T. Influence of arm position on proton density fat fraction in the liver using chemical shift-encoded magnetic resonance imaging. Magn Reson Imaging 2021;83:133-8. [PMID: 34365005 DOI: 10.1016/j.mri.2021.08.001] [Reference Citation Analysis]
241 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
242 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
243 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
244 Hui J. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7. [DOI: 10.1053/jhep.2003.50320] [Cited by in Crossref: 301] [Cited by in F6Publishing: 267] [Article Influence: 16.7] [Reference Citation Analysis]
245 Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE. Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. Cell Death Differ 2015;22:1985-94. [PMID: 25909884 DOI: 10.1038/cdd.2015.46] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
246 Mitsuyoshi H, Yasui K, Hara T, Taketani H, Ishiba H, Okajima A, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Minami M, Itoh Y. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease. Hepatol Res 2017;47:1459-68. [PMID: 28245087 DOI: 10.1111/hepr.12883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
247 Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-119. [PMID: 18384521 DOI: 10.1111/j.1478-3231.2008.01718.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 284] [Article Influence: 23.4] [Reference Citation Analysis]
248 Vanni E, Mezzabotta L, Bugianesi E. NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really? Curr Hepatology Rep 2014;13:113-8. [DOI: 10.1007/s11901-014-0225-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
249 Bencheqroun R, Duvoux C, Luciani A, Zafrani ES, Dhumeaux D. [Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis]. Gastroenterol Clin Biol. 2004;28:497-499. [PMID: 15243330 DOI: 10.1016/s0399-8320(04)94971-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
250 Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2009;39:366-373. [PMID: 19054139 DOI: 10.1111/j.1872-034X.2008.00464.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
251 Shigefuku R, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, Matsumoto N, Maeyama S, Sase S, Suzuki M. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol. 2012;47:1238-1247. [PMID: 22576023 DOI: 10.1007/s00535-012-0581-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
252 Béchade D, Blondon H, Sekkach Y, Desramé J, Algayres JP. [Review of the association between obesity and gastroesophageal reflux and its complications]. Gastroenterol Clin Biol 2009;33:155-66. [PMID: 19250782 DOI: 10.1016/j.gcb.2008.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
253 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
254 Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23:47-63. [PMID: 21326720 DOI: 10.1055/s-2006-939841] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
255 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Fassio E, Díaz S, Santa C, Elisa Reig M, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, Carlos de Souza F, Hernández N, Pinchuk L. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Annals of Hepatology 2010;9:63-9. [DOI: 10.1016/s1665-2681(19)31681-3] [Cited by in Crossref: 31] [Article Influence: 2.8] [Reference Citation Analysis]
257 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
258 Serhal R, Hilal G, Boutros G, Sidaoui J, Wardi L, Ezzeddine S, Alaaeddine N. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int 2015;2015:850246. [PMID: 26273651 DOI: 10.1155/2015/850246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
259 Mallet M, Rudler M, Thabut D. Variceal bleeding in cirrhotic patients. Gastroenterol Rep (Oxf). 2017;5:185-192. [PMID: 28852523 DOI: 10.1093/gastro/gox024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
260 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
261 Liu L, Dong B, Yu X, Liang P, Zhang D, An L. Focal Hypoechoic Tumors of Fatty Liver: Characterization of Conventional and Contrast-Enhanced Ultrasonography. Journal of Ultrasound in Medicine 2009;28:1133-42. [DOI: 10.7863/jum.2009.28.9.1133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
262 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2009.12.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
263 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
264 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1410] [Cited by in F6Publishing: 1307] [Article Influence: 78.3] [Reference Citation Analysis]
265 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
266 Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-433; quiz e50. [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023] [Cited by in Crossref: 258] [Cited by in F6Publishing: 237] [Article Influence: 25.8] [Reference Citation Analysis]
267 Halpin LE, Gunning WT, Yamamoto BK. Methamphetamine causes acute hyperthermia-dependent liver damage. Pharmacol Res Perspect 2013;1:e00008. [PMID: 25505562 DOI: 10.1002/prp2.8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
268 Lefkowitch JH. Hepatobiliary pathology: . Current Opinion in Gastroenterology 2003;19:185-93. [DOI: 10.1097/00001574-200305000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
269 Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. Ann Diagn Pathol 2018;37:83-90. [PMID: 30312882 DOI: 10.1016/j.anndiagpath.2018.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
270 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 813] [Article Influence: 79.2] [Reference Citation Analysis]
271 Navarro-jarabo JM, Ubiña-aznar E, Tapia-ceballos L, Ortiz-cuevas C, Pérez-aísa MA, Rivas-ruiz F, Andrade RJ, Perea-milla E. Hepatic steatosis and severity-related factors in obese children: Hepatic steatosis in obese children. J Gastroenterol Hepatol 2013;28:1532-8. [DOI: 10.1111/jgh.12276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
272 Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 2009;50:351-357. [PMID: 19070395 DOI: 10.1016/j.jhep.2008.09.011] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 8.8] [Reference Citation Analysis]
273 Reeder SB, Robson PM, Yu H, Shimakawa A, Hines CD, McKenzie CA, Brittain JH. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging. 2009;29:1332-1339. [PMID: 19472390 DOI: 10.1002/jmri.21751] [Cited by in Crossref: 178] [Cited by in F6Publishing: 166] [Article Influence: 14.8] [Reference Citation Analysis]
274 Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, Chaiyakunapruk N. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2017;96:e6585. [PMID: 28445256 DOI: 10.1097/MD.0000000000006585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
275 Harrison SA. Liver Disease in Patients With Diabetes Mellitus. Journal of Clinical Gastroenterology 2006;40:68-76. [DOI: 10.1097/01.mcg.0000190774.91875.d2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 8.3] [Reference Citation Analysis]
276 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
277 Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-ayuso RM, González R, Alvarez M, Hernández V, García-zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver International 2009;29:82-8. [DOI: 10.1111/j.1478-3231.2008.01823.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
278 Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci. 2014;59:365-374. [PMID: 24048683 DOI: 10.1007/s10620-013-2873-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
279 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978. [PMID: 20209604 DOI: 10.1002/hep.23527] [Cited by in Crossref: 759] [Cited by in F6Publishing: 697] [Article Influence: 69.0] [Reference Citation Analysis]
280 Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97-103. [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 251] [Article Influence: 15.8] [Reference Citation Analysis]
281 Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, Zhang X, Beier JI, Arteel GE. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther 2013;347:126-35. [PMID: 23926289 DOI: 10.1124/jpet.113.207621] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
282 Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem. 2005;38:203-217. [PMID: 15708540 DOI: 10.1016/j.clinbiochem.2004.10.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 4.1] [Reference Citation Analysis]
283 Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol 2011;5:365-70. [PMID: 21651354 DOI: 10.1586/egh.11.20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
284 Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev Gastroenterol Hepatol. 2008;2:59-79. [PMID: 19072371 DOI: 10.1586/17474124.2.1.59] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
285 Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(18): 2223-2226 [PMID: 20458758 DOI: 10.3748/wjg.v16.i18.2223] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
286 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012;56:2172-9. [PMID: 22707355 DOI: 10.1002/hep.25887] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
287 Dufour JF. NASH and thiazolidinediones: not to be taken lightly. J Hepatol 2007;47:451-3. [PMID: 17692990 DOI: 10.1016/j.jhep.2007.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
288 Sanal MG, Sarin SK. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr 2011;5:76-80. [PMID: 22813407 DOI: 10.1016/j.dsx.2012.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 167] [Article Influence: 38.0] [Reference Citation Analysis]
290 Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261. [PMID: 22008893 DOI: 10.1038/ajg.2011.327] [Cited by in Crossref: 148] [Cited by in F6Publishing: 151] [Article Influence: 14.8] [Reference Citation Analysis]
291 Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595-599. [PMID: 18662837 DOI: 10.1016/j.jhep.2008.05.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
292 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 13.8] [Reference Citation Analysis]
293 Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44 Suppl 19:89-95. [PMID: 19148800 DOI: 10.1007/s00535-008-2262-x] [Cited by in Crossref: 200] [Cited by in F6Publishing: 169] [Article Influence: 16.7] [Reference Citation Analysis]
294 Lim Y, Kim WR. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. Clinics in Liver Disease 2008;12:733-46. [DOI: 10.1016/j.cld.2008.07.007] [Cited by in Crossref: 187] [Cited by in F6Publishing: 173] [Article Influence: 14.4] [Reference Citation Analysis]
295 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 2017; 23(8): 1458-1468 [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
296 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29] [Cited by in Crossref: 642] [Cited by in F6Publishing: 407] [Article Influence: 80.3] [Reference Citation Analysis]
297 Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ;  Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555-561. [PMID: 21567436 DOI: 10.1002/hep.24418] [Cited by in Crossref: 155] [Cited by in F6Publishing: 131] [Article Influence: 15.5] [Reference Citation Analysis]
298 Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:272-82. [DOI: 10.1016/j.dld.2010.01.021] [Cited by in Crossref: 150] [Cited by in F6Publishing: 146] [Article Influence: 13.6] [Reference Citation Analysis]
299 Díaz-Montaña JJ, Díaz-Díaz N, Gómez-Vela F. GFD-Net: A novel semantic similarity methodology for the analysis of gene networks. J Biomed Inform 2017;68:71-82. [PMID: 28274758 DOI: 10.1016/j.jbi.2017.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
300 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
301 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]